Objective Compare efficacy and safety of liraglutide (1.8 mg subcutaneous once daily) and exenatide (10 mcg subcutaneous twice daily) in uncontrolled type 2 diabetes at 26 and 52 weeks. Method A retrospective observation study of uncontrolled type 2 diabetes patients who took liraglutide or exenatide in addition to their anti-diabetic medications. This study was conducted at Hamad Medical Corporation, the predominant public healthcare organization in Qatar. The primary outcome was the change in haemoglobin A1C (HbA1C) after 26 and 52 weeks. Key finding Two hundred and two patients were included in this study (liraglutide 98, exenatide 114). There was no significant HbA1C change observed between two groups at either 26 or 52 weeks (P = 0.23 and 0.40 respectively). However, more patients in the liraglutide group achieved HbA1C ≤7% at week 26. Liraglutide reduced the mean Fasting blood glucose (FBG) more than exenatide at week 26 and 52. Although both medications were associated with some benefits in other studied variables at a certain point (e.g. weight losses, blood pressure), neither of them were able to show a significant change from baseline. No patients in either group reported drug-related side effects (e.g. nausea and vomiting) or episodes of hypoglycaemia during the treatment period. Conclusions Exenatide and liraglutide resulted in similar glycaemic effects (HbA1C and fasting plasma glucose changes) in patients with type 2 diabetes who were suboptimally controlled with other anti-diabetic therapy. However, this study supports the effectiveness of both medications for weight reduction at both endpoints. A prospective large-scale study is recommended to overcome the study limitations.
Introduction
Type 2 diabetes is an increasingly common chronic disease characterized mainly by insulin resistance. [1] Many anti hyperglycaemic drugs are now available for type 2 diabetes management. Most adults with type 2 diabetes need to receive combination therapy of more than one class to achieve adequate glycaemic control. [1] To date, there is insufficient evidence to support any specific drug over another. [2] Bayesian network meta-analysis found that glucagon like peptide 1 (GLP-1) receptor agonists and insulin were the most efficacious agents in lowering haemoglobin A1C (HbA1C) after metformin failure. [2] Glucagon like peptide receptor agonists (e.g. exenatide and liraglutide) are injectable drugs that are similar to endogenous GLP-1 which usually decreased in patients with type 2 diabetes. [3] It stimulates insulin secretion (in a glucose dependent fashion), suppresses glucagon secretion, inhibits gastric motility and reduces appetite. [4, 5] GLP-1 agonists lower HbA1C by approximately 1-2%. [6] It also appears to offer advantages over other drugs by either keeping weight stable or even reducing weight while achieving good glycaemic control. [7, 8] GLP-1 receptor agonists influence weight reduction mainly through a centrally mediated mechanism that regulates the appetite, satiety and food intake. [9, 10] Another explanation of weight loss associated with GLP-1 receptor agonist treatment can be due to its gastrointestinal-related adverse effects (e.g. nausea and vomiting). [9] However, this explanation is considered weak since patients who did not experience nausea during the treatment duration lost weight as well. [11] In clinical studies that focused on the cardio-protective benefits of diabetic medications, GLP-1 agonist (exenatide and liraglutide) showed their ability to reduce blood pressure and significantly reduced total cholesterol (TC), low-density lipoprotein (LDL) and triglyceride (TG) levels compared with baseline. [12] The most common side effect associated with GLP1-receptor agonists is gastrointestinal disturbances, in which 30-45% of treated patients experiencing at least one episode of nausea, vomiting or diarrhoea. [13] GLP-1 agonists were rarely found to cause significant hypoglycaemic episodes. [14] There is only one head-to-head study comparing liraglutide versus exenatide in type 2 diabetes (LEAD-6 study). [15] LEAD-6 results showed that the mean change of HbA1C values from baseline to week 26 was significantly greater in the group treated with liraglutide than in that treated with exenatide (P < 0.0001). [15] On December 2006, exenatide (Byettaâ) was dispensed for the first time at Hamad Medical Corporation (HMC). Later on (January 2010), liraglutide (Victozaâ) was also available in the HMC pharmacy. It was unclear if liraglutide (Victozaâ) is really more effective than exenatide (Byettaâ) and needed to be added to the formulary as well. Thus, the aim of this study was to compare the effects of exenatide versus liraglutide on glycaemic control (defined as reduction in HbA1C) over 26, and 52 weeks in patients with type 2 diabetes who could not achieve adequate glycaemic control despite the use of other anti-diabetic medications.
Methods

Study design
A retrospective observation study conducted at HMC, the predominant public healthcare organization in Qatar.
Patients
Patients with type 2 diabetes who took liraglutide or exenatide in addition to their anti-diabetic medications during the period of 1st of February 2010 till 30th of January 2012 were potentially eligible for this study. Pharmacy computer system was used to identify and generate list of patients who received liraglutide or exenatide during that period. Generated patient list was screened against inclusion and exclusion criteria. Inclusion criteria were as follows: (1) type 2 diabetes patients using either Victozaâ (liraglutide 1.8 mg subcutaneous once daily) or Byettaâ (exenatide 10 mcg subcutaneous twice daily), (2) being compliant with studied drugs for at least 52 weeks (1 year), (3) had suboptimal glycaemic control at baseline (HbA1C 7.1-11.0%), (4) had a body mass index (BMI) ≤45 kg/m 2 , (5) had been treated with lifestyle modification (diet and exercise) and with at least one other anti-diabetic drug. Patients were considered to be compliant if the studied drugs were dispensed at regular basis and patients did not run-out of medication at any point during treatment duration.
Exclusion criteria were as follows: (1) had been treated with herbals or drugs that promote weight loss within
Procedure
Medical records of eligible patients were retrospectively reviewed from both (1) the patient's paper-based medical file and (2) the patient's electronic file (i.e. medical database, e-viewer and pharmacy database). Data collection sheets were completed by the investigators. All data were rechecked twice to prevent any missed data.
Primary and secondary objectives
Primary: To compare the efficacy between liraglutide (1.8 mg subcutaneous once daily) versus exenatide (10 mcg subcutaneous twice daily) measured by the changing of HbA1C from baseline to 26 weeks, and 52 weeks.
Secondary: To compare the effects of liraglutide and exenatide at baseline, 26 weeks, and 52 weeks in terms of:
1 Efficacy: Percentage of patients achieved target HbA1C ≤7%, fasting plasma glucose (FPG), body weight and BMI, systolic and diastolic blood pressure (DBP), fasting lipids profile levels (TC, LDL, high-density lipoprotein (HDL), TG). 2 Safety: Gastrointestinal disturbances (nausea, vomiting or diarrhoea), hypoglycaemic episodes (defined as FPG < 3.9 mmol/l (70 mg/dl) at any time during the study period and/or dispensing of glucagon showed on the pharmacy dispensing system, kidney and liver function (e.g. serum creatinine, blood urea nitrogen (BUN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT)).
Statistical analysis
Descriptive statistics were used to summarize demographic and all other clinical characteristics of the patients. Quantitative variables means between the two independent groups were analysed using an unpaired t-test and a Mann-Whitney U-test. Associations between two or more qualitative variables were assessed using a chi-square test or Fisher's exact test as appropriate. Quantitative variables means at different time points (baseline, 26, and 52 weeks) were compared using repeated-measure analysis of variance (ANOVA) followed by Bonferroni's corrections for a multiple comparison test. Relationships between two quantitative variables were examined using Pearson's correlation coefficients. A two-sided P value < 0.05 was considered to be statistically significant. All statistical analyses were done using statistical packages SPSS 19.0 (SPSS Inc. Chicago, IL, USA).
Ethical consideration
The study protocol, data collection sheet and waiver consent were approved by the HMC research and ethics committee.
Results
Patients' characteristics
Of 371 identified patients, only 212 patients met the inclusion criteria and were included in this study. There were 114 patients in Exenatide group, and 98 in liraglutide group. The most common reason for excluding patients was the duration use of exenatide or liraglutide was <1 year (n = 134). Female gender was dominant in this study, representing around 73% in both groups. The mean age for all of the study's patients was 53 years. A round half of the patients in this study were aged between 50 and 59 years. Patients were diagnosed with diabetes for a mean duration of 7.7 years. Generally, there were no significant differences in all of the patients' demographics, co-existing chronic diseases and concurrent medications (including anti-diabetic medications) between the two groups except for renal impairment and diabetic neuropathy (Table 1) .
Primary outcome
The mean HbA1C readings of both exenatide and liraglutide were statistically insignificant over the observation periods of 26 and 52 weeks (Table 2) . However, comparing the mean change of HbA1C values between the two groups, HbA1C was increased from the baseline to 26 weeks of interval (0.098 AE 0.177) in the exenatide group, while it decreased in the liraglutide group (À0.213 AE 0.180). Despite this, the treatment difference between the two groups was statistically insignificant (estimated treatment difference (ETD) À0.310; 95% CI À0.19 to 0.81; P = 0.23).
At week 52, the opposite relationship was shown, in which HbA1C values increased more in the liraglutide group than in the exenatide group (Figure 1a ). The mean change from the baseline to 52 weeks interval was more in the liraglutide group (1.399 AE 1.608) than in the exenatide group (0.077 AE 0.203) and was statistically insignificant (ETD À1.322; 95% CI À4.30 to 1.65; P = 0.40).
The proportion of participants achieving HbA1C targets of 7% or less was higher in the liraglutide than in the exenatide group at 26 weeks (20% versus 6.4% respectively) and was statistically significant (P = 0.008). Similarly, a higher proportion of liraglutide participants achieved HbA1C targets ≤7% at 52 weeks (16.4% versus 9%); however, it was statistically insignificant (P = 0.19) (Figure 1b ).
Secondary outcomes Efficacy
Fasting blood glucose: The mean FPG was reduced in both groups at 26 and 52 weeks. This reduction was statistically significant in the liraglutide group at the three time intervals: baseline to 26 weeks, baseline to 52 weeks ( Table 3 ). The mean change from the baseline to 26 weeks interval was greater in the liraglutide group (À1.099 AE 0.518) than in the exenatide group (À0.122 AE 0.432) and was statistically insignificant (P = 0.15). Comparable results were found in exenatide and liraglutide groups at the 52-week interval (À0.616 AE 0.618; 67, À1.150 AE 0.519, P = 0.52 respectively).
Body weight: The mean BMI and body weight were reduced at 26 and 52 weeks, in which BMI reduction was statistically significant in both liraglutide and exenatide groups at both time intervals: 26 weeks (P = 0.023, P = 0.015 respectively) and 52 weeks (P = 0.002, P = 0.002 respectively). On the other hand, body weight reduction was statistically significant at both 26 and 52 weeks only in exenatide group, while the liraglutide group was statistically significant only at 52 weeks.
Blood pressure: At week 26, the systolic blood pressure (SBP) increased in the exenatide-treated group, while it slightly decreased in the liraglutide group. On the other hand, the DBP decreased in the exenatide-treated group, while it increased in the liraglutide group (Figure 2a,b) . At 52 weeks, both the systolic and DBP reduced in both treatment groups (compared with week 26) and the reduction was more in the liraglutide group than in the exenatide group (Figure 2a,b) . Comparing the change of blood pressure between the two groups retrieved no statistical difference at any timepoint.
Lipid level profile: TC and LDL were reduced in the liraglutide group at both timepoints (26 and 52 weeks) but it was statistically significant only at the baseline 52 weeks of interval. Other parameters (HDL, TGs) were statistically insignificant over the observation periods. All lipid profile parameters (TC, LDL, HDL and TG) were statistically insignificantly changed in exenatide group at both timepoints (Figure 2c,d ). Comparing two groups together, none of the profile parameters showed any statistically significant difference.
Safety
None of the patients in either groups reported any GI side effects (nausea, vomiting and diarrhoea) or hypoglycaemic episodes. For other safety parameters regarding kidney and liver functions, none of the changes in these parameters were significant at any timepoints except for creatinine in the liraglutide group at 52 weeks (P = 0.001) (Table 4) . Overall, the exenatide group had a better safety profile than the liraglutide group in all kidney and liver function parameters in both timepoints, except for AST at 26 weeks. For example, at week 52, the mean reduction in ALT from baseline was (À1.483 AE 1.278) in the exenatide group, 
Discussion
This is the first retrospective head-to-head comparison study for both safety and efficacy outcomes of liraglutide versus the exenatide in the Middle East region. This study can guide the local and the regional practice and utilization of the study's medications.
Primary outcome
The UK Prospective Diabetes Study (UKPDS) found that a reduction of 1% in HbA1C was associated with a 37% decrease in micro-vascular complications and a 21% decrease in mortality associated with diabetes. [16] Thus, selection of HbA1C reduction as a primary outcome is clinically relevant and well justified. In the current study, results showed that in type 2 diabetic patients with inadequate glycaemic control on other anti-diabetic medications, neither the addition of 1.8 mg liraglutide nor 10 mcg exenatide provided significant glycaemic control after 26 or 52 weeks of treatment compared to baseline. The beneficial effects of liraglutide over exenatide seen at week 26 were aligned with those reported in the only liraglutide versus exenatide head-to-head study (LEAD-6). [15] The LEAD-6 results showed that the mean change of HbA1C values from baseline to week 26 was significantly greater in the group treated with liraglutide than in that treated with exenatide (P < 0.0001).
Unlike the previous studies of either liraglutide or exenatide when each drug was studied separately, in the present study, liraglutide 1.8 mg once daily reduced HbA1C by a mean of 0.213% after 26 weeks compared with a reduction of 1% in the LEAD-2 study, [17] 1.1% in the LEAD-1 study, [18] 1.3% in the LEAD-5 study [19] and 1.5% in both the LEAD-4 and DURATION-6 (exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes a randomized, open-label study) studies. [20, 21] Additionally, the current results and the previous studies' results, exenatide 10 mcg twice daily slightly increased HbA1C values by a mean of 0.098% and 0.077% at 26 and 52 weeks respectively. This increase was not consistent with other trials in which HbA1C was reduced by approximately 1%. [11, 12, [22] [23] [24] The reasons for this unexpected difference in HbA1C changes noted in this study for both liraglutide and exenatide are unknown; however, previous pharmacological exposure, study population or medication compliance might have contributed to the differences.
Secondary outcomes Fasting plasma glucose
Fasting plasma glucose is an important measure of glycaemic control, where fasting hyperglycaemia contributes to the chronic complications of diabetes. [11] In this study, FPG was decreased in both groups at 26 and 52 weeks, but the decrease achieved statistical significance only in the liraglutide group. Although liraglutide also showed greater FPG reduction over exenatide in the LEAD-6 study, the mean reduction at 26 weeks reported in the LEAD-6 study (3.2 mmol/l for liraglutide, and 2.9 mmol/l for exenatide) was much higher than what was shown in the current study (1.1 mmol/l for liraglutide, and 0.12 mmol/l for exenatide). [25] In the current study, the mean reduction in FPG in the exenatide group was out of the reduction range (1-2 mmol/l) reported in other trials at both 26 and 52 weeks. [11, 12, 23, 26, 27] Unpredictably, liraglutide patients continued to have FPG reduction at week 52 despite the elevation of their HbA1C at that endpoint. Therefore, reduction in FPG is not always translated into a reduction in HbA1C.
Body weight, blood pressure and lipid profile
In line with the beneficial effects of exenatide and liraglutide in weight reduction approved in previous trials, [7, 8] the current study showed that patients' weights were significantly reduced at 26 and 52 weeks in both groups compared to their baseline weight, except for the liraglutide group at 26 weeks. However, there were no treatment differences between the two groups at both timepoints similar to the LEAD-6 study (P = 0.2235). [25] Noteworthy that both exenatide and liraglutide showed reductions in blood pressure (SBP and DBP) occurred in the two groups at both 26 and 52 weeks. Although the SBP reduction reported in the LEAD-6 trial was much greater in both groups than reported in this study. [25] Moreover, they demonstrated beneficial effects on lipids parameters (e.g. TC, TG and LDL); liraglutide provided better non-significant lipid improvement versus exenatide with exception of HDL which improved more in exenatide patients. In spite of both groups experiencing an unpredicted elevation of TG at week 52, liraglutide produced a more substantial TG elevation than exenatide did. However, the mean change in lipid levels in this study was lower than that reported in previous trials. [12, 23] 
Hypoglycaemic episodes
In previous trials, GLP-1 agonists were not associated with a significant increase in hypoglycaemic episodes unless combined with other drugs that elicited hypoglycaemia. [26] There is no event of hypoglycaemia in this study neither as minor nor major episodes. In the LEAD-6 study, no major hypoglycaemia occurred with liraglutide while only two episodes happened with exenatide patients. [25] 
Gastrointestinal disturbances
The proportion of patients experiencing nausea in LEAD-6 was initially similar in the two groups; however, nausea was resolved more quickly in patients treated with liraglutide than in those treated with exenatide. [25] In the current study, unfortunately, none of the patients in both groups reported any GI side effects as nothing was documented in their files.
Strengths and limitations
This study had several strengths that are worth mentioning. The notable strengths of this study that it was being the first of its kind in Qatar, and indeed the entire Arabian Gulf region, to present a head-to-head comparison of exenatide (10 mcg twice daily) versus liraglutide (1.8 mg once daily) in type 2 diabetic patients other than the LEAD-6 study. Moreover, a longer duration when compared to the LEAD-6 study, which gives deep insight about the long-term effect of liraglutide and exenatide. In addition to, There were no statistically significant differences between the two groups regarding other anti-diabetic medications that patients were concurrently taking with the studied drug, providing the study with the advantage of eliminating any possible confounder factors that could affect the reliability of the study results' and ensuring that the reported results truly represented the effect of the studied drugs rather than the effect of other underlined causes.
Conclusion
In conclusion and on the basis of the results of this study, it seemed that there was no statistically significant efficacy difference between liraglutide and exenatide in terms of reduction in HbA1C and FPG. However, this study supports the effectiveness of both medications for weight reduction where both medications caused weight loss (and consequently BMI reduction) at both endpoints (26 and 52 weeks). Although these medications were associated with some benefits in other studied variables at a certain point, neither of them was able to show a significant change from baseline. No patients in either group reported drugrelated side effects (e.g. nausea and vomiting) or episodes of hypoglycaemia during the treatment period.
Overall, the current study highlights the importance of further studies to be done to compare the efficacy and safety of liraglutide and exenatide in type 2 diabetic patients. A prospective large-scale study is recommended to overcome the previously mentioned limitations. Until that, this study hopefully will be used to better inform healthcare providers, and this will eventually translate into an increase in the health benefits and awareness for the patients.
